Investigation of Scutellaria Barbata’s immunological mechanism against thyroid cancer using network pharmacology and experimental validation

Abstract Thyroid cancer (TC) is the most common endocrine malignancy, with a rapidly increasing global incidence. Scutellariae Barbatae Herba (SBH) exhibits significant antitumor activity; however, its mechanism against TC remains unclear. This study aims to explore the immunotherapeutic mechanism o...

Full description

Saved in:
Bibliographic Details
Main Authors: Gen Ouyang, Yuangui Zhu, Zhehao Ouyang
Format: Article
Language:English
Published: Nature Portfolio 2025-01-01
Series:Scientific Reports
Subjects:
Online Access:https://doi.org/10.1038/s41598-025-86733-1
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832585717679652864
author Gen Ouyang
Yuangui Zhu
Zhehao Ouyang
author_facet Gen Ouyang
Yuangui Zhu
Zhehao Ouyang
author_sort Gen Ouyang
collection DOAJ
description Abstract Thyroid cancer (TC) is the most common endocrine malignancy, with a rapidly increasing global incidence. Scutellariae Barbatae Herba (SBH) exhibits significant antitumor activity; however, its mechanism against TC remains unclear. This study aims to explore the immunotherapeutic mechanism of SBH in treating TC through network pharmacology, bioinformatics analysis, and experimental validation. In the TCMSP database, the active components and potential targets of SBH were screened to construct a drug-component-target-disease network. TC targets were then filtered, and common targets were selected to build a protein-protein interaction network. GO and KEGG enrichment analyses were performed. The expression, prognosis, and immunotherapeutic roles of core genes were validated using TCGA databases. Molecular docking demonstrated the binding interactions between core components and targets. Finally, in vitro experiments were conducted to validate the results of the network pharmacology analysis. 14 active components and 29 potential targets of SBH in treating TC were identified from the TCMSP database. PPI network analysis highlighted SPP1 as a key target. GO enrichment analysis involved 722 biological processes, 24 cellular components, and 73 molecular functions. KEGG enrichment analysis suggested that the anticancer effect of SBH might be mediated through signaling pathways such as AGE-RAGE and PI3K-Akt. TCGA data indicated that SPP1 is highly expressed in TC and is associated with diagnosis, pathological stage, N stage, and gender of TC patients. Additionally, SPP1 expression correlated with the infiltration of 24 types of immune cells, with the highest correlation observed with macrophages. Molecular docking demonstrated that SPP1 has high binding stability with quercetin, Rhamnazin, and Salvigenin, with binding energies of -8.117, -7.494, and − 7.202 kJ∙mol − 1, respectively. Experimental validation showed that quercetin inhibited the growth of TC cells in a dose-dependent manner. Protein results indicated that quercetin downregulated SPP1 mRNA and protein expression. This study combines database predictions with experimental validation to reveal the potential mechanisms of SBH against TC, providing effective strategies for the immunotherapy of TC.
format Article
id doaj-art-753e1bca00e44b98ab46fdceb0b53bd4
institution Kabale University
issn 2045-2322
language English
publishDate 2025-01-01
publisher Nature Portfolio
record_format Article
series Scientific Reports
spelling doaj-art-753e1bca00e44b98ab46fdceb0b53bd42025-01-26T12:33:04ZengNature PortfolioScientific Reports2045-23222025-01-0115111510.1038/s41598-025-86733-1Investigation of Scutellaria Barbata’s immunological mechanism against thyroid cancer using network pharmacology and experimental validationGen Ouyang0Yuangui Zhu1Zhehao Ouyang2Jiangxi Province Hospital of Integrated Chinese and Western MedicineJiangxi Province Hospital of Integrated Chinese and Western MedicineJiangxi University of Chinese MedicineAbstract Thyroid cancer (TC) is the most common endocrine malignancy, with a rapidly increasing global incidence. Scutellariae Barbatae Herba (SBH) exhibits significant antitumor activity; however, its mechanism against TC remains unclear. This study aims to explore the immunotherapeutic mechanism of SBH in treating TC through network pharmacology, bioinformatics analysis, and experimental validation. In the TCMSP database, the active components and potential targets of SBH were screened to construct a drug-component-target-disease network. TC targets were then filtered, and common targets were selected to build a protein-protein interaction network. GO and KEGG enrichment analyses were performed. The expression, prognosis, and immunotherapeutic roles of core genes were validated using TCGA databases. Molecular docking demonstrated the binding interactions between core components and targets. Finally, in vitro experiments were conducted to validate the results of the network pharmacology analysis. 14 active components and 29 potential targets of SBH in treating TC were identified from the TCMSP database. PPI network analysis highlighted SPP1 as a key target. GO enrichment analysis involved 722 biological processes, 24 cellular components, and 73 molecular functions. KEGG enrichment analysis suggested that the anticancer effect of SBH might be mediated through signaling pathways such as AGE-RAGE and PI3K-Akt. TCGA data indicated that SPP1 is highly expressed in TC and is associated with diagnosis, pathological stage, N stage, and gender of TC patients. Additionally, SPP1 expression correlated with the infiltration of 24 types of immune cells, with the highest correlation observed with macrophages. Molecular docking demonstrated that SPP1 has high binding stability with quercetin, Rhamnazin, and Salvigenin, with binding energies of -8.117, -7.494, and − 7.202 kJ∙mol − 1, respectively. Experimental validation showed that quercetin inhibited the growth of TC cells in a dose-dependent manner. Protein results indicated that quercetin downregulated SPP1 mRNA and protein expression. This study combines database predictions with experimental validation to reveal the potential mechanisms of SBH against TC, providing effective strategies for the immunotherapy of TC.https://doi.org/10.1038/s41598-025-86733-1Scutellariae Barbatae HerbaNetwork pharmacologyThyroid cancerImmunomodulatory effectsMolecular docking
spellingShingle Gen Ouyang
Yuangui Zhu
Zhehao Ouyang
Investigation of Scutellaria Barbata’s immunological mechanism against thyroid cancer using network pharmacology and experimental validation
Scientific Reports
Scutellariae Barbatae Herba
Network pharmacology
Thyroid cancer
Immunomodulatory effects
Molecular docking
title Investigation of Scutellaria Barbata’s immunological mechanism against thyroid cancer using network pharmacology and experimental validation
title_full Investigation of Scutellaria Barbata’s immunological mechanism against thyroid cancer using network pharmacology and experimental validation
title_fullStr Investigation of Scutellaria Barbata’s immunological mechanism against thyroid cancer using network pharmacology and experimental validation
title_full_unstemmed Investigation of Scutellaria Barbata’s immunological mechanism against thyroid cancer using network pharmacology and experimental validation
title_short Investigation of Scutellaria Barbata’s immunological mechanism against thyroid cancer using network pharmacology and experimental validation
title_sort investigation of scutellaria barbata s immunological mechanism against thyroid cancer using network pharmacology and experimental validation
topic Scutellariae Barbatae Herba
Network pharmacology
Thyroid cancer
Immunomodulatory effects
Molecular docking
url https://doi.org/10.1038/s41598-025-86733-1
work_keys_str_mv AT genouyang investigationofscutellariabarbatasimmunologicalmechanismagainstthyroidcancerusingnetworkpharmacologyandexperimentalvalidation
AT yuanguizhu investigationofscutellariabarbatasimmunologicalmechanismagainstthyroidcancerusingnetworkpharmacologyandexperimentalvalidation
AT zhehaoouyang investigationofscutellariabarbatasimmunologicalmechanismagainstthyroidcancerusingnetworkpharmacologyandexperimentalvalidation